Search Result

Results for "

Prostaglandin D-3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PGE synthase (1) Prostaglandin Receptor (4) Adrenergic Receptor (1) Apoptosis (2) Autophagy (1) Caspase (1) COX (6) Cytochrome P450 (1) Drug Metabolite (1) Fluorescent Dye (2) Isotope-Labeled Compounds (9) Lipoxygenase (1) Mitophagy (1) Monoamine Oxidase (1) NF-κB (2) NO Synthase (2) p38 MAPK (1) Parasite (1) Phosphodiesterase (PDE) (1) Virus Protease (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (3) Endocrinology (1) Infection (3) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Targets Recommended: Prostaglandin Receptor PGE synthase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14654S

Aspirin-d3 Acetylsalicylic acid-d₃; ASA-d₃	Isotope-Labeled Compounds COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Aspirin-d₃ is the deuterium labeled Aspirin (HY-14654). Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .

HY-B1111S1

Amitraz-d3 BTS-27419-d₃	Isotope-Labeled Compounds Adrenergic Receptor Monoamine Oxidase Parasite	Infection Endocrinology
Amitraz-d₃ is the deuterium labeled Amitraz. Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.

HY-P4406

*Abz-AGLA-Nba* 1 Publications Verification	Fluorescent Dye	Others
Abz-AGLA-Nba is a fluorogenic substrate for the determination of protease activity. Abz-AGLA-Nba is hydrolyzed to release aminoacyl benzimide (Abz-AGLA) and 2-naphthylaminoacyl (Nba). The product Abz-AGLA produced by this hydrolysis reaction is fluorescent under ultraviolet light and can emit a fluorescent signal .

HY-17509S

Deracoxib-d3 SC 046-d₃; SC 46-d₃; SC 59046-d₃	Isotope-Labeled Compounds COX Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

HY-P4406A

*Abz-AGLA-Nba TFA*	Fluorescent Dye	Others
Abz-AGLA-Nba TFA is a fluorogenic substrate for the determination of protease activity. Abz-AGLA-Nba TFA is hydrolyzed to release aminoacyl benzimide (Abz-AGLA) and 2-naphthylaminoacyl (Nba). The product Abz-AGLA produced by this hydrolysis reaction is fluorescent under ultraviolet light and can emit a fluorescent signal .

HY-113444

Prostaglandin D3 PGD3	Prostaglandin Receptor	Cardiovascular Disease
Prostaglandin D3 (PGD3) is a prostaglandin that acts as an inhibitor of platelet aggregation and a modulator of autonomic neurotransmission in humans .

HY-166363S

Beraprost-d3 TRK-100-d₃; ML 1129-d₃	Isotope-Labeled Compounds Prostaglandin Receptor	Cardiovascular Disease
Beraprost-d₃ (TRK-100-d₃) is deuterium labeled (Rac)-Beraprost. (Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca ²⁺ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .

HY-W746847

Epibetulinic acid-d3	Isotope-Labeled Compounds Prostaglandin Receptor NO Synthase	Inflammation/Immunology
Epibetulinic acid-d₃ is the deuterium labeled Epibetulinic acid (HY-N0223). Epibetulinic acid exhibits potent inhibitory effects on NO and prostaglandin E2 (PGE2) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with IC₅₀s of 0.7 and 0.6 μM, respectively. Anti-inflammatory activity .

HY-17474S

Parecoxib-d3 SC 69124-d₃	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-B0531S

Triflusal-d3	Isotope-Labeled Compounds COX NF-κB Phosphodiesterase (PDE) NO Synthase Prostaglandin Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Triflusal-d₃ is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and *prostaglandin* synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .

HY-W778179

Benoxaprofen-13C,d3 LRCL 3794-¹³C,d₃	Isotope-Labeled Compounds COX Cytochrome P450 Lipoxygenase PGE synthase	Inflammation/Immunology
Benoxaprofen- ¹³C, d₃ is the ¹³C-labeled Benoxaprofen (HY-13568). Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .

HY-B1398S

Ampyrone-d3 4-Aminoantipyrine-d₃	Isotope-Labeled Compounds COX Drug Metabolite	Neurological Disease Inflammation/Immunology Cancer
Ampyrone-d₃ is the deuterium labeled Ampyrone (HY-B1398). Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .

Cat. No.	Product Name	Target	Research Area

HY-P4406

*Abz-AGLA-Nba* 1 Publications Verification	Fluorescent Dye	Others
Abz-AGLA-Nba is a fluorogenic substrate for the determination of protease activity. Abz-AGLA-Nba is hydrolyzed to release aminoacyl benzimide (Abz-AGLA) and 2-naphthylaminoacyl (Nba). The product Abz-AGLA produced by this hydrolysis reaction is fluorescent under ultraviolet light and can emit a fluorescent signal .

HY-P4406A

*Abz-AGLA-Nba TFA*	Fluorescent Dye	Others
Abz-AGLA-Nba TFA is a fluorogenic substrate for the determination of protease activity. Abz-AGLA-Nba TFA is hydrolyzed to release aminoacyl benzimide (Abz-AGLA) and 2-naphthylaminoacyl (Nba). The product Abz-AGLA produced by this hydrolysis reaction is fluorescent under ultraviolet light and can emit a fluorescent signal .

Cat. No.	Product Name	Chemical Structure

HY-14654S

Aspirin-d3
Aspirin-d₃ is the deuterium labeled Aspirin (HY-14654). Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .

Aspirin-d3

Aspirin-d₃ is the deuterium labeled Aspirin (HY-14654). Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .

HY-B1111S1

Amitraz-d3
Amitraz-d₃ is the deuterium labeled Amitraz. Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.

HY-17509S

Deracoxib-d3
Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

Deracoxib-d3

Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

HY-166363S

Beraprost-d3
Beraprost-d₃ (TRK-100-d₃) is deuterium labeled (Rac)-Beraprost. (Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca ²⁺ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .

Beraprost-d3

Beraprost-d₃ (TRK-100-d₃) is deuterium labeled (Rac)-Beraprost. (Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca ²⁺ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .

HY-W746847

Epibetulinic acid-d3
Epibetulinic acid-d₃ is the deuterium labeled Epibetulinic acid (HY-N0223). Epibetulinic acid exhibits potent inhibitory effects on NO and prostaglandin E2 (PGE2) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with IC₅₀s of 0.7 and 0.6 μM, respectively. Anti-inflammatory activity .

HY-17474S

Parecoxib-d3
Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

Parecoxib-d3

Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.

HY-B0531S

Triflusal-d3
Triflusal-d₃ is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and *prostaglandin* synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .

Triflusal-d3

Triflusal-d₃ is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .

HY-W778179

Benoxaprofen-13C,d3
Benoxaprofen- ¹³C, d₃ is the ¹³C-labeled Benoxaprofen (HY-13568). Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .

Benoxaprofen-13C,d3

Benoxaprofen- ¹³C, d₃ is the ¹³C-labeled Benoxaprofen (HY-13568). Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .

HY-B1398S

Ampyrone-d3
Ampyrone-d₃ is the deuterium labeled Ampyrone (HY-B1398). Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .

Ampyrone-d3

Ampyrone-d₃ is the deuterium labeled Ampyrone (HY-B1398). Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.